SOUTH KOREA – Samsung Biologics announced that it has agreed to pay US$2.3 billion for Biogen’s stake in their nearly decade-long biosimilars joint venture Samsung Bioepis. The announcement follows a…
Read MoreSamsung Biologics buys out Biogen in biosim venture for US$2.3B
